Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
5 reports, 3 independent
Updated Aug 16
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Royalty Pharma filed reports with the SEC while Morgan Stanley boosted its share position.1 source
Royalty Pharma filed a prospectus with the SEC.1 source
Keep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Establishment Labs filed with the SEC and was listed on the Nasdaq stock exchange on August 29, 2026.
- Prospect Capital Corporation expects to file a report with the Securities and Exchange Commission.
- Alterity Therapeutics Limited disclosed corporate transactions with the Securities and Exchange Commission on September 1, 2026.
- QuickLogic Corporation filed a disclosure with the Securities and Exchange Commission on September 16, 2026.
- SEC received filings regarding stock holdings from Williams Companies on September 22, 2026.
Coverage
Newest first; wire copies grouped- tickerreport.com
- dailypolitical.com
- GlobeNewswireRoyalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offerin